托法替布治疗溃疡性结肠炎的安全性和疗效:OCTAVE Open 开放标签长期扩展研究最终分析,治疗长达 7.0 年
OCTAVE Open 开放标签长期扩展研究纳入 944 例溃疡性结肠炎患者,其中 769 例(81.5%)初始接受托法替布 10 mg 每日两次。总暴露 2440.8 患者年,观察至 7.0 年,死亡发生率为 0.25(95%CI 0.09-0.54)/100 患者年,严重感染为 1.61(95%CI 1.14-2.20)/100 患者年。至第 36 个月,5 mg 和 10 mg 每日两次组分别有 66.9% 和 40.3% 达临床应答。
要点
- OCTAVE Open 中 81.5%(769/944)患者初始接受托法替布 10 mg 每日两次。
- 总暴露 2440.8 患者年,死亡发生率 0.25/100 患者年(95%CI 0.09-0.54)。
- 至第 36 个月,5 mg 与 10 mg 每日两次组临床应答率分别为 66.9% 与 40.3%。
核心结论
- 托法替布在长达 7.0 年的治疗中显示出稳定的安全性。
- 截至第 36 个月收集的数据支持托法替布在 52 周维持研究之后的长期疗效。
研究设计与样本
- OCTAVE Open 为开放标签长期扩展研究,主要目标是评估托法替布长期安全性和耐受性,疗效为次要目标。
- 纳入 OCTAVE Induction 1&2 无应答者以及 OCTAVE Sustain 完成者/治疗失败者,共 944 例,其中 769 例(81.5%)初始接受托法替布 10 mg 每日两次。
- OCTAVE Open 基线时处于缓解的患者接受托法替布 5 mg 每日两次,其余患者接受 10 mg 每日两次。
- 观察期长达 7.0 年;疗效终点从 Mayo 评分衍生,报告至第 36 个月(末次计划内镜访视)。
主要发现
- 在所有患者(暴露 2440.8 患者年)中,死亡发生率为 0.25(95%CI 0.09-0.54)/100 患者年。
- 严重感染发生率为 1.61(95%CI 1.14-2.20)/100 患者年,带状疱疹(非严重和严重)为 3.16(95%CI 2.47-3.97)/100 患者年。
- 机会性感染发生率为 0.87(95%CI 0.54-1.33)/100 患者年,主要不良心血管事件为 0.16(95%CI 0.04-0.42)/100 患者年。
- 恶性肿瘤(不包括非黑色素瘤皮肤癌)发生率为 1.03(95%CI 0.67-1.52)/100 患者年,非黑色素瘤皮肤癌为 0.75(95%CI 0.45-1.19)/100 患者年。
- 深静脉血栓发生率为 0.04(95%CI 0.00-0.23)/100 患者年,肺栓塞为 0.21(95%CI 0.07-0.48)/100 患者年。
关键数值与推荐
- 至第 36 个月,托法替布 5 mg 每日两次组与 10 mg 每日两次组分别有 66.9% 与 40.3% 显示临床应答。
- 至第 36 个月,托法替布 5 mg 每日两次组与 10 mg 每日两次组分别有 64.6% 与 37.1% 出现内镜改善。
- 至第 36 个月,托法替布 5 mg 每日两次组与 10 mg 每日两次组分别有 58.9% 与 33.7% 维持或达到缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open-label, long-term extension study. AIMS: The primary objective of OCTAVE Open was to assess the safety and tolerability of long-term tofacitinib in patients with ulcerative colitis; evaluating efficacy was a secondary objective. METHODS: Eligible patients included OCTAVE Induction 1&2 non-responders and OCTAVE Sustain completers/treatment failures. Patients in remission at OCTAVE Open baseline received tofacitinib 5 mg b.d.; all others received 10 mg b.d. Incidence rates (unique patients with events/100 patient-years) for adverse events of special interest were calculated; ≤7.0 years of observation. Efficacy endpoints derived from Mayo score were reported ≤36 months (last scheduled endoscopy visit). RESULTS: In OCTAVE Open, 769 of 944 patients (81.5%) initially received tofacitinib 10 mg b.d. Among all patients (2440.8 patient-years of exposure), incidence rates (IRs; 95% confidence intervals) for deaths and adverse events of special interest were: deaths, 0.25 (0.09-0.54); serious infections, 1.61 (1.14-2.20); herpes zoster (non-serious and serious), 3.16 (2.47-3.97); opportunistic infections, 0.87 (0.54-1.33); major adverse cardiovascular events, 0.16 (0.04-0.42); malignancies (excluding non-melanoma skin cancer), 1.03 (0.67-1.52); non-melanoma skin cancer, 0.75 (0.45-1.19); deep vein thrombosis, 0.04 (0.00-0.23); pulmonary embolism, 0.21 (0.07-0.48). At Month 36, 66.9% and 40.3% showed clinical response, 64.6% and 37.1% had endoscopic improvement, and 58.9% and 33.7% maintained or achieved remission, with tofacitinib 5 and 10 mg b.d. respectively. CONCLUSION: Tofacitinib demonstrated consistent safety up to 7.0 years. Data collected up to Month 36 support long-term efficacy beyond the 52-week maintenance study.
引用
- Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2021. PMID: 34854095. doi:10.1111/apt.16712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。